This is a Phase I, combination of single ascending dose/multiple ascending dose to evaluate the safety and pharmacokinetics of birinapant as a single agent in patients infected with chronic Hepatitis B virus.
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Birinapant (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- Sponsors TetraLogic Pharmaceuticals
- 07 Aug 2015 According to the media release of TetraLogic pharmaceuticals, this study is expect to initiate at multiple sites in India in early 2016 and the timing of results will depend upon enrollment rates.
- 07 Aug 2015 New trial record